Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s68. https://doi.org/10.25251/skin.6.supp.68